Immunotherapy-Induced Acute Hepatitis in the Elderly: The Case of a Patient with Urothelial Carcinoma and a Review of the Literature
By:
References
- Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;May 15. doi:<a href="https://doi.org/10.1038/s41571-019-0218-0." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/s41571-019-0218-0.</a>
- Postow M, Wolchok J. Patient selection criteria and toxicities associated with checkpoint inhibitor immunotherapy 2018. Uptodate.com.
- Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; Jul 1;28(suppl_4):iv119–iv142. doi:<a href="https://doi.org/10.1093/annonc/mdx225." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1093/annonc/mdx225.</a>
- Johncilla M, Misdraji J, Pratt DS, et al. Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases. Am J Surg Pathol. 2015;39.
- Kim KW, Ramaiya NH, Krajewski KM, et al. Ipilimumab associated hepatitis: imaging and clinicopathological findings. Invest New Drugs. 2013;31.
- Karamchandani, D. M., Chetty, R. Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists’ perspective. J Clin Pathol. 2018;71: 665–671.
- Ziemer M, Koukoulioti E, Beyer S, et al. Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids. J Hepatology. 2017;66(3):657–659.
- Aivazian K., et al. Histopathology of pembrolizumab-induced hepatitis: a case report. Pathology. 2017;49(7):789–792.
- Friedman CF, Horvat TZ, Minehart J, et al. Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80+). J Clin Oncology. 2016;34(15_Suppl.):10009.
- European Medicine Agency Keytruda (pembrolizumab) authorization. https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda.
- Wu Z, Lai L, Li M, Zhang L, Zhang W. Acute liver failure caused by pembrolizumab in a patient with pulmonary metastatic liver cancer: A case report. Medicine (Baltimore). 2017;96(51):e9431. doi:<a href="https://doi.org/10.1097/MD.0000000000009431." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1097/MD.0000000000009431.</a>
- Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26:2375–2591.
- Elias R, Karantanos T, Sira E, et al. Immunotherapy comes of age: immune aging & checkpoint inhibitors. J Geriatr Oncol. 2017;8(3):229–235.
- Daste A, Domblides C, Gross-Goupil M, et al. Immune checkpoint inhibitors and elderly people: a review. Eur J Cancer. 2017;82:155–166.
- Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;Jun 10;36(17):1714–1768. doi:<a href="https://doi.org/10.1200/JCO.2017.77.6385." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/JCO.2017.77.6385.</a>
- Thompson JA, Schneider BJ, Brahmer J et al. Management of immunotherapy related toxicities, Version 2.2019–April 8, 2019. NCCN Clinical Practice Guidelines in Oncology.
- Suzman DL, Pelosof L, Rosenberg A, et al. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents. Liver Int, 2018;38:976–987.
- Kleiner DE, Berman D. Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci. 2012;57:2233.
- Holstein Y, Kapiteijn E, Bastiaannet E, van den Bos F, Portielje J, de Glas NA. Efficacy and adverse events of immunotherapy with checkpoint inhibitors in older patients with cancer. Drugs Aging. 2019 Oct;36(10):927–938. doi:<a href="https://doi.org/10.1007/s40266-019-00697-2." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s40266-019-00697-2.</a> PMID: 31317421; PMCID: PMC6764930.
- Singh H, Kim G, Maher VE, et al. FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancers. J Clin Oncology. 2016;34(15_Suppl.):10010.
- Gomes F, Woolley S, Califano R, et al. MA 1007 elderly lung cancer patients on immunotherapy: preliminary results from the ELDERS study. J Thorac Oncol. 2017;12(11):S1841–1842.
- Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376:1015.
- Balar AV, Castellano D, O’Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 2017;18:1483.
- U.S. Department of Health and Human Services National Institutes of Health National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. November 27, 2017.
- Chmiel KD, Suan D, Liddle C. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol. 2011;Mar;29(9):e237–40.
Language: English
Page range: 28 - 33
Submitted on: Apr 11, 2021
Accepted on: Jul 15, 2021
Published on: Feb 1, 2022
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 times per year
Keywords:
Related subjects:
© 2022 Ioannou Alexandros, Papaxoinis Georgios, Dimitroulopoulos Dimitrios, Tryfonopoulos Dimitrios, Gouveris Panagiotis, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.